Lilly(US:LLY) Zhi Tong Cai Jing·2025-08-26 12:29Group 1 - Eli Lilly announced that its oral weight loss therapy orforglipron achieved primary goals in Phase 3 trials and will proceed with global registration [1] - In the ATTAIN-2 trial, orforglipron demonstrated an average weight loss of 22.9 pounds (10.5%) over 72 weeks at the highest dose, with an intention-to-treat analysis showing a 9.6% weight loss at the 36mg dose [1] - The international study involved over 1,600 adults with obesity or overweight and type 2 diabetes, achieving all primary and key secondary endpoints, including a reduction in A1C levels by 1.3% to 1.8% from a baseline of 8.1% [1] Group 2 - The safety profile of orforglipron is consistent with other GLP-1 receptor agonists, but treatment discontinuation rates due to adverse events ranged from 6.1% to 10.6% across three dosage levels, compared to 4.6% in the placebo group [2] - The overall treatment discontinuation rates for the 6mg, 12mg, and 36mg groups were 19.1%, 22.3%, and 20.5%, respectively, while the placebo group had a rate of 20% [2] - Eli Lilly has completed the clinical data package necessary for the global registration submission of orforglipron, with full study results to be presented at future medical conferences [2]